Multicenter Phase II Clinical Trial of Nilotinib for Patients with Imatinib-Resistant or Intolerant CML From the East Japan CML Study Group (EJCML) Trial: Evaluation of Molecular Responses by the BCR-ABL1 Mutational Status and Plasma Trough Concentration of Nilotinib
Year: 2012
Type: article
Source: Blood
Authors: Naoto Takahashi, Masatomo Miura, Jun Kuroki, Kinuko Mitani, Atsushi Kitabayashi, Osamu Sasaki, Hideo Kimura, Kiyotoshi Imai, Norifumi Tsukamoto, Hideyoshi Noji, Takeshi Kondo, Akihisa Kuwayama, Mutsuhito Motegi, Yuichi Kato, Kaoru Takahashi, Masayuki Mita, Hajime Saito, Chikashi Yoshida, Yoshihiro Torimoto, Tomofumi Kimura, Yuji Wano, Jun Nomura, Satoshi Yamamoto, Ko Mayama, Riko Honma, Tomohiro Sugawara, Shinji Sato, Atsushi Shinagawa, Akihiko Chubachi, Hideo Harigae, Kenichi Sawada
Institutions: Akita University, Akita University Hospital, Yuri Kumiai General Hospital, Dokkyo Medical University, Miyagi Prefectural Hospital Organization, Sapporo Hokuyu Hospital, Gunma University Hospital, Fukushima Medical University, Hokkaido University Hospital, Yamagata University, Shirakawa Kosei General Hospital, National Hospital Organization Mito Medical Center, Asahikawa Medical University, Iwate Prefectural Central Hospital, Tohoku Medical and Pharmaceutical University Wakabayashi Hospital, Sapporo City General Hospital, Hirosaki University, Yamagata Prefectural Central Hospital, Osaki Citizen Hospital, Okitama Public General Hospital, Hitachi General Hospital, Koto Hospital, Tohoku University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2586689352